Navigation Links
TALEN® Access by Cellectis Bioresearch Receives "Most Innovative New Service 2011" Award at Life Science Awards

PARIS, July 5, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary of Cellectis (Alternext: ALCLS) and specialist in genome customization, has received the "Most Innovative New Service 2011" award from Select Biosciences for their TALEN® Access service offering. TALENs(1) allow for customized gene modifications, providing researchers across multiple disciplines with a powerful and now affordable new tool. This prize was presented at the Life Science Awards preceding the European Lab Automation conference held in Hamburg June 30 and July 1, 2011.

Each year the Life Science Awards celebrate the best of the industry's achievements worldwide. The awards are judged by a panel of international industrial and academic experts.

"We are very honored to receive this award. It rewards well our team's tremendous work in coming up with such an extremely high quality offer at an affordable price, only a few months after having acquired the technology," stated Dr. Luc Selig, VP Sales and Marketing at Cellectis bioresearch.

"We are the first to market TALEN® and are bringing in new clients every day," added Marc Le Bozec, CEO of Cellectis bioresearch. "Our ambition is to convert biology researchers around the world to genome customization. This community of 3 million is now exploring this completely new approach that allows them to better do things they were already doing, but most importantly opens up so many new possibilities. We estimate the market potential to be in the millions of euro within 10 years."

Today, TALEN® Access is paired with individualized project management support to better meet the needs of Cellectis bioresearch clients.

(1) TALEN: Transcription Activator-Like Effector Nuclease

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific nucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The genome customization products and services can be purchased online from Check the website for more information.

Follow Cellectis bioresearch on twitter :

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.

For further information about Cellectis, visit our website at:

Follow Cellectis on twitter :


This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company s objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
2. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
3. Mymetics Corporation Information to be Available Through Standard & Poors Market Access Program
4. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
5. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
6. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
8. USDA Awards $1.5 Million to Expand Access to High-Quality Critical Care in Rural Communities
9. Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods
10. GeneNews provides Centocor access to its osteoarthritis program
11. Jatropha World 2009 Advance Access: Surprisingly Candid Interview Series Examines Biofuel Predictions Compared to Fossil Fuels
Post Your Comments:
(Date:10/9/2015)...  DePuy Synthes Trauma* announced today the U.S. launch ... Technology**, the only pre-hydrated demineralized cancellous bone tissue matrix ... ankle, hand and wrist), including fusion, and for filling ... 2015 Orthopaedic Trauma Association (OTA) Annual Meeting. ... bone growth) and osteoinductive 2,3 (stimulates new bone ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to ... separating those cells from their surroundings for research, diagnostics, and cell therapy—also known ... address this, Ann Arbor-based startup Akadeum Life Sciences is developing a ...
(Date:10/8/2015)... CARDIFF, UK (PRWEB) , ... October 08, 2015 , ... ... to literally see inside the living brain, providing a new tool to study how ... work is reported by Woo June Choi and Ruikang Wang of the UW Department ...
(Date:10/8/2015)... 8, 2015  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; ... for cancer and associated pain, announced today that Dr. Henry ... presenting at the Aegis Capital Corporation 2015 Growth ... Capital Corporation 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 ... @ The Wynn in Las Vegas, NV , ...
Breaking Biology Technology:
(Date:10/8/2015)... , Oct. 8, 2015 Synaptics ... human interface solutions, announced today that it will ... fiscal 2016 on Thursday, October 22, 2015, after ... a corresponding conference call for analysts and investors ... which management may discuss forward-looking information.    ...
(Date:10/8/2015)... , October 8, 2015 ... or the "Company"), a biometric authentication company focused ... of the Wocket® smart wallet announces that revenues ... were approximately $410,000 compared with $113,00 for the ... the 9 months ended September 30, 2015 were ...
(Date:10/7/2015)... -- NXTD ) ("NXT-ID" or the "Company"), ... commerce market and creator of the Wocket® smart wallet ... term executive at American Express has been appointed to ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... the Wocket® smart wallet announces Mr. Stanley E. ...
Breaking Biology News(10 mins):